Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amgen
Pharma
BMS, Merck, Amgen and more face near-term generic woes: Leerink
As patent expirations near for many of the world’s top drugmakers, companies will need to be diligent about M&A, according to a new Leerink report.
Fraiser Kansteiner
Nov 13, 2024 10:57am
Amgen, AZ's Tezspire excels in phase 3 rhinosinusitis trial
Nov 8, 2024 3:31pm
Boehringer tops reputation rankings among CV patient groups
Oct 31, 2024 11:32am
Amgen reaps Horizon buyout rewards in Q3, preps biosim launches
Oct 31, 2024 7:50am
Amgen gears up to launch Eylea biosim as Regeneron plots appeal
Oct 23, 2024 10:16am
Amgen can't sidestep investor lawsuit over $10.7B tax bill
Oct 2, 2024 9:14am
